Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ensysce Biosciences (ENSC) EPS (Weighted Average and Diluted) (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$1.38 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 2071.43% to -$1.38 in Q3 2025 year-over-year; TTM through Sep 2025 was -$6.35, a 91.9% increase, with the full-year FY2024 number at -$11.45, up 83.74% from a year prior.
  • EPS (Weighted Average and Diluted) was -$1.38 for Q3 2025 at Ensysce Biosciences, down from -$0.65 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.48 in Q4 2022 to a low of -$66.87 in Q4 2023.
  • A 5-year average of -$13.11 and a median of -$1.38 in 2025 define the central range for EPS (Weighted Average and Diluted).
  • Biggest YoY gain for EPS (Weighted Average and Diluted) was 375.31% in 2022; the steepest drop was 9087.32% in 2022.
  • Ensysce Biosciences' EPS (Weighted Average and Diluted) stood at -$0.54 in 2021, then skyrocketed by 375.31% to $1.48 in 2022, then plummeted by 4618.24% to -$66.87 in 2023, then soared by 95.62% to -$2.93 in 2024, then skyrocketed by 52.9% to -$1.38 in 2025.
  • Per Business Quant, the three most recent readings for ENSC's EPS (Weighted Average and Diluted) are -$1.38 (Q3 2025), -$0.65 (Q2 2025), and -$1.39 (Q1 2025).